Jefferson Institute for Bioprocessing Capacity Update March 2023: Cell & Gene

Source: Jefferson Institute for Bioprocessing (JIB)

The Jefferson Institute for Bioprocessing (JIB) has undertaken a facility expansion program that will empower pilot-scale production of early phase clinical cell and gene therapy material for clients at its Lower Gwynedd (Montgomery County) facility.

By increasing production area to include four additional BSL2 clean room suites, this milestone effort is expected to see cGMP production capacity active by early summer 2023. With a focus on cell and gene therapy and expanded analytical capabilities, the project aligns with clients’ needs.

The expansion will provide Current Good Manufacturing Practices (cGMP) capabilities, which will allow for phase I/II clinical production.

access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online